AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16202499 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (LP) with strong air-blowing (s)
Number of subjects: 24
Study 16202499 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental adhesive SSB-200 (SSB) with strong air-blowing (s)
Number of subjects: 24
Study 12975072 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady noise of a car engine recorded on a compact disc
Number of subjects: 36
Study 12975072 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 36
Study 10709161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg (6 days single-dose and 2 days multiple-dose 10 mg q 4 hours for three doses, total daily dose of 30 mg on Days 7 and 8)
Number of subjects: 20
Study 10709161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10709161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 20
Study 9180662 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral glucose tolerance test (OGTT)
Number of subjects: 95
Study 8261152 — intervention group
Group type: EXPERIMENTAL
Intervention: Chordal preservation
Number of subjects: 100
Study 8261152 — intervention group
Group type: COMPARATOR
Intervention: No chordal preservation
Number of subjects: 100
Study 3928054 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 12
Study 3928054 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide
Number of subjects: 12
Study 30730799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice (1000ppm) - Group B
Number of subjects: 150
Study 30730799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro® Tooth Crème (CTC) - Group C
Number of subjects: 150
Study 30730799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse Plus® (TMP) - Group D
Number of subjects: 150
Study 30730799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice followed by CTC - Group E
Number of subjects: 150
Study 30730799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice followed by TMP - Group F
Number of subjects: 150
Study 30730799 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice - Group A
Number of subjects: 150
Study 30107381 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH‐convective)
Number of subjects: 20
Study 30107381 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous hemodialysis (CVVHD‐diffusive)
Number of subjects: 20
Study 30107381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CVVH and CVVHD
Number of subjects: 20
Study 27379745 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) training
Number of subjects: 130
Study 27379745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 25208199 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol craving task
Number of subjects: 45
Study 25208199 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking craving task
Number of subjects: 45
Study 22324943 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alone
Number of subjects: 38
Study 22324943 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol and calcium
Number of subjects: 38
Study 22324943 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate and calcium
Number of subjects: 38
Study 22324943 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 38
Study 19772883 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline + Risperidone
Number of subjects: 40
Study 19772883 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Risperidone
Number of subjects: 40
Study 17073859 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the tibial nerve (TN group, n=32)
Number of subjects: 96
Study 17073859 — intervention group
Group type: EXPERIMENTAL
Intervention: Two separate 15-ml injections targeting both tibial and common peroneal nerves (TN + CPN group, n=32)
Number of subjects: 96
Study 17073859 — intervention group
Group type: COMPARATOR
Intervention: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the common peroneal nerve (CPN group, n=32)
Number of subjects: 96
Study 17073859 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the tibial nerve (TN group)
Number of subjects: 96
Study 17073859 — intervention group
Group type: EXPERIMENTAL
Intervention: Two separate 15-ml injections targeting both tibial and common peroneal nerves (TN + CPN group)
Number of subjects: 96
Study 17073859 — intervention group
Group type: COMPARATOR
Intervention: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the common peroneal nerve (CPN group)
Number of subjects: 96
Study 15204149 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg per day of cyclosporine A (CsA) for 4 weeks
Number of subjects: 20
Study 15204149 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg per day of cyclosporine A (CsA) for 12 weeks
Number of subjects: 20
Study 11334198 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS heparin management test (HMT)
Number of subjects: 50
Study 11334198 — intervention group
Group type: COMPARATOR
Intervention: Activated clotting time (ACT)
Number of subjects: 50
Study 9761506 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken meal
Number of subjects: 8
Study 9761506 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef meal
Number of subjects: 8
Study 8199076 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rupture of membranes (amniotomy)
Number of subjects: 1463
Study 8199076 — intervention group
Group type: COMPARATOR
Intervention: Late rupture of membranes (control)
Number of subjects: 1463
Study 3599344 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg chlorthalidone
Number of subjects: 222
Study 3599344 — intervention group
Group type: COMPARATOR
Intervention: 25 mg chlorthalidone
Number of subjects: 222
Study 3599344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 30904934 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 61
Study 30904934 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 61
Study 29473960 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT)
Number of subjects: 128
Study 27198187 — intervention group
Group type: COMPARATOR
Intervention: High mycoprotein (132 g)
Number of subjects: 55
Study 27198187 — intervention group
Group type: COMPARATOR
Intervention: Medium mycoprotein (88 g)
Number of subjects: 55
Study 27198187 — intervention group
Group type: COMPARATOR
Intervention: Low mycoprotein (44 g)
Number of subjects: 55
Study 24515510 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU of daily oral vitamin D3
Number of subjects: 48
Study 24515510 — intervention group
Group type: COMPARATOR
Intervention: 400 IU of daily oral vitamin D3
Number of subjects: 48
Study 22931552 — intervention group
Group type: EXPERIMENTAL
Intervention: Delorme's procedure
Number of subjects: 130
Study 22931552 — intervention group
Group type: COMPARATOR
Intervention: Resection rectopexy
Number of subjects: 130
Study 20870000 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioral therapy
Number of subjects: 144
Study 20870000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy
Number of subjects: 144
Study 20870000 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 144
Study 16574200 — intervention group
Group type: COMPARATOR
Intervention: FXIII subunit A (FXIIIA) levels in sepsis patients (n=40)
Number of subjects: 40
Study 16574200 — intervention group
Group type: COMPARATOR
Intervention: FXIII cross‐linking activity (FXIIICA) levels in sepsis patients (n=40)
Number of subjects: 40
Study 16574200 — intervention group
Group type: COMPARATOR
Intervention: Specific activity of FXIII (SA(FXIII)) in sepsis patients (n=40)
Number of subjects: 40
Study 16574200 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific activity of FXIII (SA(FXIII)) in non-survivors vs survivors
Number of subjects: 40
Study 16574200 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific activity of FXIII (SA(FXIII)) in septic shock vs severe sepsis
Number of subjects: 40
Study 16266408 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Networks (ANNs)
Number of subjects: 238
Study 16266408 — intervention group
Group type: COMPARATOR
Intervention: Logistic Regression
Number of subjects: 238
Study 12010112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low family support
Number of subjects: 170
Study 12010112 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent mother‐daughter communication
Number of subjects: 170
Study 12010112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother‐daughter communication about preventing acquired immune deficiency syndrome
Number of subjects: 170
Study 12010112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low perceived family support
Number of subjects: 170
Study 12010112 — intervention group
Group type: COMPARATOR
Intervention: Perceived access or financial issues
Number of subjects: 170
Study 10385714 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic scleroligation
Number of subjects: 51
Study 10385714 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation
Number of subjects: 51
Study 8681488 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 0
Study 8681488 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-modified interferon alfa-2a
Number of subjects: 0
Study 1810260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.d.)
Number of subjects: 8
Study 1810260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1810260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine and Theophylline (500 mg b.d.)
Number of subjects: 8
Study 1810260 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Theophylline (500 mg b.d.)
Number of subjects: 8
Study 6194037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 5%, 10%, and 20% intravenously for 1 hour with secretin (8.2 pmol . kg‐1 . h‐1)
Number of subjects: 6
Study 6194037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 5%, 10%, and 20% intravenously without secretin
Number of subjects: 6
Study 6194037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 5%, 10%, and 20% perfused into the intestine
Number of subjects: 6
Study 6194037 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Intralipid by intestinal infusion for 2 hours while 10% Intralipid was infused intravenously during the second hour
Number of subjects: 6
Study 30758406 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTG+CAF+EMD application
Number of subjects: 38
Study 30758406 — intervention group
Group type: COMPARATOR
Intervention: SCTG+CAF
Number of subjects: 38
Study 28577362 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels
Number of subjects: 12966
Study 28577362 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest uric acid quartile
Number of subjects: 12966
Study 28577362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia group
Number of subjects: 12966
Study 28577362 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 1 mg/dl increase in uric acid concentration
Number of subjects: 12966
Study 27037729 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist wound healing dressings
Number of subjects: 95
Study 27037729 — intervention group
Group type: COMPARATOR
Intervention: Gauze
Number of subjects: 95
Study 24438620 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS)
Number of subjects: 50
Study 22019891 — intervention group
Group type: EXPERIMENTAL
Intervention: BBR+CPA
Number of subjects: 89
Study 22019891 — intervention group
Group type: COMPARATOR
Intervention: MET+CPA
Number of subjects: 89
Study 22019891 — intervention group
Group type: COMPARATOR
Intervention: Placebo+CPA
Number of subjects: 89
Study 19581546 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier advergame condition
Number of subjects: 30
Study 19581546 — intervention group
Group type: EXPERIMENTAL
Intervention: Less healthy advergame condition
Number of subjects: 30
Study 19581546 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study 17264107 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tolerable energy density
Number of subjects: 49
Study 17264107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed energy density
Number of subjects: 49
Study 17264107 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 49
Study 15118280 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (330 mg daily)
Number of subjects: 212
Study 15118280 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet agent or anticoagulant
Number of subjects: 212
Study 15118280 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm subjects (control group)
Number of subjects: 212
Study 11071827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 2208
Study 11071827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2208
Study 9382660 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTU care (inhaled adrenergic agonists and steroids for up to 9 hours)
Number of subjects: 222
Study 9382660 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTU care
Number of subjects: 222
Study 9382660 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care (routine therapy in a hospital ward)
Number of subjects: 222
Study 8104738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective beta-blocker propranolol
Number of subjects: 24
Study 8104738 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1-selective blocker metoprolol
Number of subjects: 24
Study 8104738 — intervention group
Group type: COMPARATOR
Intervention: Control patients without CHF
Number of subjects: 24
Study 3956111 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 15
Study 3956111 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization
Number of subjects: 15
Study 3956111 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 3956111 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise post-immobilization
Number of subjects: 15
Study 3956111 — intervention group
Group type: COMPARATOR
Intervention: Maximal exercise post-control
Number of subjects: 15
Study 3956111 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise post-training
Number of subjects: 15
Study 3956111 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training
Number of subjects: 15
Study 3956111 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-immobilization
Number of subjects: 15
Study 3343502 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconnected urinary catheter drainage system
Number of subjects: 202
Study 3343502 — intervention group
Group type: COMPARATOR
Intervention: Standard urinary catheter drainage system
Number of subjects: 202
Study 3343502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 202
Study 31831094 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of Fe-rich or Fe-fortified foods during 6-23 months of age
Number of subjects: 745
Study 31831094 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial consumption of cows'/goats' milk at 10-12 months
Number of subjects: 745
Study 31831094 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial consumption of high protein-based food at 7-9 months
Number of subjects: 745
Study 31831094 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite infant feeding index in the highest tertile of overall feeding quality
Number of subjects: 745
Study 30753467 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg)
Number of subjects: 20
Study 30753467 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study 27730462 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGB
Number of subjects: 103
Study 27730462 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMizer Extra
Number of subjects: 103
Study 26364181 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab every 3 weeks
Number of subjects: 27
Study 24490152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity elastic resistance training for 2 minutes per day (n = 15)
Number of subjects: 30
Study 24490152 — intervention group
Group type: COMPARATOR
Intervention: Control receiving weekly email-based information on general health (n = 15)
Number of subjects: 30
Study 21633285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir-based therapy
Number of subjects: 255
Study 21633285 — intervention group
Group type: COMPARATOR
Intervention: Switch to nevirapine-based regimen
Number of subjects: 255
Study 18326960 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (ARB) monotherapy at maximal dose
Number of subjects: 81
Study 17132971 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg b.i.d.; n=203)
Number of subjects: 404
Study 17132971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=201)
Number of subjects: 404
Study 14585866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 14585866 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10699097 — intervention group
Group type: EXPERIMENTAL
Intervention: Early low-dose indomethacin therapy
Number of subjects: 384
Study 10699097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 9316359 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 300
Study 9316359 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 300
Study 8450099 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cognitive-behavior therapy (8-week group intervention)
Number of subjects: 24
Study 8450099 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cognitive-behavior therapy (8-week group intervention)
Number of subjects: 24
Study 8450099 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 24
Study 3512025 — intervention group
Group type: EXPERIMENTAL
Intervention: C. parvum, 2 mg/m2 IV, repeated eight times at three weekly intervals
Number of subjects: 115
Study 3512025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no C. parvum treatment)
Number of subjects: 115
Study 3512025 — intervention group
Group type: EXPERIMENTAL
Intervention: C. parvum
Number of subjects: 115
Study 3512025 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 31672172 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and green tea extract (GR, n=8)
Number of subjects: 30
Study 31672172 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (R, n=8)
Number of subjects: 30
Study 31672172 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (G, n=7)
Number of subjects: 30
Study 31672172 — intervention group
Group type: COMPARATOR
Intervention: Control (C, n=7)
Number of subjects: 30
Study 28768544 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic titanium clip placement
Number of subjects: 27
Study 28768544 — intervention group
Group type: COMPARATOR
Intervention: Control group (palpitation of nodules or esophageal wall mucosal thickening)
Number of subjects: 27
Study 26234063 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-end anastomosis
Number of subjects: 80
Study 26234063 — intervention group
Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 80
Study 23959902 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent video recordings of live music performances
Number of subjects: 0
Study 23959902 — intervention group
Group type: COMPARATOR
Intervention: Sound recordings of music performances
Number of subjects: 0
Study 23959902 — intervention group
Group type: COMPARATOR
Intervention: Recordings with both video and sound
Number of subjects: 0
Study 21361732 — intervention group
Group type: EXPERIMENTAL
Intervention: O2A2 group (omeprazole 20 mg twice/day plus amoxicillin 500 mg 4 times/day)
Number of subjects: 128
Study 21361732 — intervention group
Group type: EXPERIMENTAL
Intervention: O2A1 group (omeprazole 20 mg twice/day plus amoxicillin 250 mg 4 times/day)
Number of subjects: 128
Study 21361732 — intervention group
Group type: EXPERIMENTAL
Intervention: O1A2 group (omeprazole 20 mg once/day plus amoxicillin 500 mg 4 times/day)
Number of subjects: 128
Study 21361732 — intervention group
Group type: EXPERIMENTAL
Intervention: O1A1 group (omeprazole 20 mg once/day plus amoxicillin 250 mg 4 times/day)
Number of subjects: 128
Study 21361732 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose groups (omeprazole higher dose)
Number of subjects: 128
Study 21361732 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 extensive metabolizers
Number of subjects: 128
Study 21361732 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent antibiotic susceptibility‐driven proton pump inhibitor‐based triple therapy
Number of subjects: 128
Study 18675870 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV(Vero)
Number of subjects: 817
Study 18675870 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV(Mkc)
Number of subjects: 817
Study 17182505 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 0
Study 12660485 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined deep sclerectomy and phacoemulsification (PDS)
Number of subjects: 42
Study 12660485 — intervention group
Group type: COMPARATOR
Intervention: Deep sclerectomy with implant (DS)
Number of subjects: 42
Study 10981569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg every 8 h
Number of subjects: 50
Study 10981569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9503938 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoxide inhalation (15-minute sessions)
Number of subjects: 51
Study 9503938 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoxide inhalation
Number of subjects: 51